Rodman & Renshaw and MedKnowledge present the latest in a series of medical expert conference calls.

Senior Biotechnology Analyst Michael G. King, Jr. hosts the call, featuring Arthur F. Kavanaugh, MD, Professor of Clinical Medicine, Director, Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology, University of California, San Diego.

Dr. Arthur Kavanaugh is a Professor of Clinical Medicine and Director at the Center for Innovative Therapy, Division of Rheumatology, Allergy and Immunology at the University of California at San Diego. Dr. Kavanaugh’s research interest include innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases, prognostic and predictive factors for outcomes in rheumatic diseases and research programs on approaches to various immunologic diseases, particularly novel biologic therapies. Dr. Kavanaugh has authored dozens of publications in manuscripts, chapters and books.

Rodman & Renshaw and MedKnowledge present the latest in a series of medical expert conference calls.

Senior Biotechnology Analysts Michael G. King, Jr. & Vernon Bernardino host the call, featuring Silvio E. Inzucchi, MD, Professor of Medicine, Section of Endocrinology, Yale University (Clinical Director, Yale-New Haven Hospital, Director of Yale Diabetes Center)

Vernon T. Bernardino, Senior BioTech Analyst at Rodman & Renshaw, hosted a call with Sherwyn L. Schwartz (pictured right), MD, CEO and Chief Medical Officer, Diabetes and Glandular Disease Research Inc., and Giovanni Solinas, PhD, Director of the Laboratory of Medical Stress Biology, Dept. of Medicine, University of Fribourg, Switzerland

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that Ramnarain “Joe” Jaigobind has joined Rodman as Head of Global Capital Markets and President of Middle East, India and Japan markets. Mr. Jaigobind joins Rodman from Maxim Group with a team of eight professionals, significantly strengthening Rodman’s Global Capital Markets practice.

Mr. Jaigobind has significant experience in the public equity markets. He will spearhead Rodman’s initiatives to expand its origination and distribution of initial and secondary public offerings and its participation in syndicated public offerings led by other firms. These enhanced capabilities will complement Rodman’s #1 ranked position in PIPE offerings1, by both broadening the range of capital markets options available to its corporate clients and expanding its investor client base.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has completed the acquisition of COSCO Capital Management LLC and its related companies, a leading private investment bank focused on the oil and gas sectors in the United States and Canada. Rodman previously announced that it had entered into definitive agreements to acquire the COSCO companies on May 12, 2008.

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has added two Senior Managing Directors, Steven Wasserman and Allan Schwartz, to its new Global Capital Markets Group.

Messrs. Wasserman and Schwartz have wide-ranging and significant experience in the origination of both public offerings and strategic advisory engagements in the shipping, technology, homeland security and restaurants sectors, and substantial experience with Special Purpose Acquisition Companies (SPACS) financing transactions.

The addition of Messrs. Wasserman and Schwartz, and the creation of the Global Capital Markets Group demonstrate Rodman’s commitment to broadening and deepening its capital markets capabilities, and building on the firm’s longstanding #1 ranking in PIPE offerings.1

Rodman & Renshaw Capital Group, Inc (NASDAQ: RODM - News), today announced that Michael Lacovara, Chief Executive Officer, will be presenting at Sandler O’Neill & Partners’ 2008 Global Exchange and Electronic Trading Conference taking place at the Grand Hyatt New York, on Friday, June 6 at 8.30 a.m. ET.

A live webcast and audio conference of the presentation will be available. The webcast may be accessed through the Rodman & Renshaw Capital Group, Inc. website at: http://www.thomson-webcast.net/us/dispatching/SOP_20080605 and the audio conference will be available by dialing: 800-659-1966 and stating the passcode: “Session 2.”

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that Senior Biotechnology Analyst Dr. Elemer Piros has been named one of the “World’s Top Analysts” by the Financial Times (“FT”). The FT, in a May 16, 2008 report and survey published in conjunction with StarMine, examined the 2007 performance of research analysts from Asia, Europe and the US, and honored as the “World’s Best” the top three stock pickers and earnings estimators in each industry.

Dr. Piros, who specializes in biotechnology, was recognized as one of the top three analysts in the entire Pharmaceutical category.

Michael Lacovara, Chief Executive Officer, commented: “The FT and StarMine have confirmed what Rodman and its clients have long known – Elemer Piros is a leading light in biotech research, a committed and insightful analyst, and a cornerstone of our distinguished life science research team.”

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced its results for the first quarter ended March 31, 2008.

Net revenue for the quarter was $15.2 million, representing an increase of 5% from $14.5 million in the fourth quarter of 2007. The Company reported net income of $1.1 million, or $0.03 per share, for the quarter, compared to a net loss of $1.6 million, or ($0.05) per share, for the fourth quarter of 2007. The Company reported net income on a non-U.S. GAAP basis of $1.7 million, or $0.05, per share, compared to a net loss of $1.1 million or ($0.03) per share for the fourth quarter of 2007.1

“During this quarter we have continued to expand our franchise and add talented professionals to our team and businesses to our platform,” commented Michael Lacovara, Chief Executive Officer of Rodman & Renshaw. “We continued to execute on our strategic plan for the year, despite the very challenging market environment.”

Transaction Will Create the Rodman Energy Group

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News), today announced that it has entered into a definitive agreement to acquire the operating assets of COSCO Capital Management LLC and its related companies, a leading private investment bank focused on the oil and gas sectors, principally in the United States and Canada. Concurrent with the closing of the transaction, Rodman will create the Rodman Energy Group, which will continue and expand COSCO’s existing investment advisory and finance practice for companies and funds active in the energy sector. The group will be led by Cameron O. Smith, COSCO’s Founder and Senior Managing Director and will include COSCO’s other principals, who are seasoned oil and gas sector investment banking professionals. The transaction is expected to close during the second fiscal quarter.

Forms JV with Aceras Partners, LLC to Make Principal Investments in Biotechnology

Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM - News) today announced the formation of Aceras BioMedical LLC (“Aceras BioMedical”), a joint venture through which Rodman, in partnership with Aceras Partners, LLC (“Aceras Partners”), an established team of biotech research and investment specialists, will make principal investments in early-stage biotechnology and life sciences companies. The founders of Aceras Partners formed the firm following their tenures most recently at Paramount BioSciences, LLC. Collectively, the Aceras Partners team has completed numerous product licenses and acquisitions, leading to the formation of many notable private and public biotechnology companies, which produced significant returns to early-stage investors.

By: Doug Hughes

1/16/2008
We have reopened the newsletter due to the bank stock crash for 2008:
Today CITI bank reported their biggest loss in 192 years. That about says it all.

Source: SVILUPPO DEL MEDITERRANEO

The Euro-Mediterranean Region is one of expanding opportunity. Including the all EU, Euro-Med Region, with 720 millions inhabitants could become a common market by 2010. Such a large market – bigger by far than China – is one that businesses and investors must reckon with.

The Mediterranean region, among three continents, enjoyed its greatest prosperity when it was open to trade, ideas, innovation and private enterprise.

Nowadays, between the two shores, the Mediterranean area holds the world record gap for GDP differential per capita: 1 to 10 between South and North, versus 1 to 7 between Mexico and USA.

Location: Hilton Philadelphia, PA

Are you prepared for the upcoming FDA and state requirements?

Secure Pharma introduces you to a cross-channel audience to share and develop best practices, as well as collaborate on solving the issues that plague your supply chain and compromise product integrity.

Listen and learn from the known thought leaders in the industry so that you can address the vulnerabilities within your supply chain, and the looming state and federal mandates, while maintaining financial and patient health.

Register for Secure Pharma today and transform your supply chain into one that is financially and operationally secure, and fully compliant with state and federal laws. Your management team, distribution partners, and customers will thank you for it!

Official Site

Special Update 11/9/2007:

Banks continued their sell-off this week creating the best investment ideas in over 10 years.
They are also hitting other groups hard now, stocks like DBD, that make ATM’s for banks look interesting and a new issue MV, that does a lot of bank processing, that spun off from MI also looks attractive in this bloodbath, both also have options.